DUBLIN–(BUSINESS WIRE)–The “Hepatitis C – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Hepatitis C pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis C R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis C.
Hepatitis C Emerging Drugs Chapters
This segment of the Hepatitis C report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hepatitis C Emerging Drugs
TG-2349: Dongguan HEC TaiGen Biopharmaceuticals
TG-2349 (Furaprevir) is a HCV protease inhibitor. It is a novel direct acting antivirals for the all-oral treatment of chronic hepatitis C virus (HCV) infection. The drug has completed Phase III clinical evaluation in combination with DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected patients.
SH229: Nanjing Sanhome Pharmaceutical
SH229 is a NS5B inhibitor that is being developed by Nanjing Sanhome Pharmaceutical for the treatment of chronic hepatitis C virus infection. The drug is currently in Phase II/III clinical studies combined with fixed-dose Daclatasvi dihydrochloride (DCV) tablets for the treatment of hepatitis C virus infection.
Hepatitis C: Therapeutic Assessment
This segment of the report provides insights about the different Hepatitis C drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Hepatitis C
There are approx. 70+ key companies which are developing the therapies for Hepatitis C. The companies which have their Hepatitis C drug candidates in the most advanced stage, i.e. Phase III include, Dongguan HEC TaiGen Biopharmaceuticals.
Hepatitis C: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis C therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis C drugs.
Hepatitis C Report Insights
- Hepatitis C Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Hepatitis C Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hepatitis C drugs?
- How many Hepatitis C drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis C?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hepatitis C therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hepatitis C and their status?
- What are the key designations that have been granted to the emerging drugs?
Companies Mentioned
- Dongguan HEC TaiGen Biopharmaceuticals
- Nanjing Sanhome Pharmaceutical
- PharmaEssentia
- HEC Pharm
- Atea Pharmaceuticals
- AllaChem
- HepC
- Sunshine Lake Pharma
- GeneCure Biotechnologies
- Therapure Innovations
- Adaptimmune
- Orgenesis
- Dekk-Tec
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1ds3ri
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900